| Literature DB >> 30573851 |
Yaseen M Arabi1, Mohammed Al-Balwi2, Ali H Hajeer3, Dunia Jawdat4, Musharaf Sadat5, Hasan M Al-Dorzi5, Hani Tamim6, Lara Afesh5, Walid Almashaqbeh4, Haitham Alkadi7, Deemah Alwadaani7, G K UdayaRaja8, Ibrahim B Al Abdulkareem9, Abdulaziz Al-Dawood5.
Abstract
The effect of short-term caloric restriction on gene expression in critically ill patients has not been studied. In this sub-study of the PermiT trial (Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults Trial- ISRCTN68144998), we examined gene expression patterns in peripheral white blood cells (buffy coat) associated with moderate caloric restriction (permissive underfeeding) in critically ill patients compared to standard feeding. Blood samples collected on study day 1 and 14 were subjected to total RNA extraction and gene expression using microarray analysis. We enrolled 50 patients, 25 in each group. Among 1751 tested genes, 332 genes in 12 pathways were found to be significantly upregulated or downregulated between study day 1 and 14 (global p value for the pathway ≤ 0.05). Using the heatmap, the differential expression of genes from day 1 to 14 in the permissive underfeeding group was compared to the standard feeding group. We further compared gene expression signal intensity in permissive underfeeding compared standard feeding by constructing univariate and multivariate linear regression models on individual patient data. We found differential expression of several genes with permissive underfeeding, most notably those related to metabolism, autophagy and other cellular functions, indicating that moderate differences in caloric intake trigger different cellular pathways.Entities:
Mesh:
Year: 2018 PMID: 30573851 PMCID: PMC6301949 DOI: 10.1038/s41598-018-36007-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline Characteristics of patients in the permissive underfeeding and standard feeding groups.
| Variable | Permissive underfeeding n = 25 | Standard feeding n = 25 | P-value |
|---|---|---|---|
| Age (yrs), median (Q1, Q3) | 28.0 (23.0, 58.1) | 44.7 (27.5, 64.7) | 0.21 |
| Female sex, n (%) | 4 (16.0) | 4 (16.0) | 1.00 |
| Height (cm), median (Q1, Q3) | 170 (164, 180) | 170 (165, 173) | 0.45 |
| Weight (kg), median (Q1, Q3) | 78 (54, 90) | 82 (70, 88) | 0.32 |
| BMI (kg/m2), median (Q1, Q3) | 27.2 (21.9, 33.2) | 29.4 (24.8, 32.3) | 0.46 |
| Diabetes, n (%) | 7 (28.0) | 8 (32.0) | 0.78 |
| Inclusion blood glucose (mmol/L), median (Q1, Q3) | 8.7 (7.6, 13.1) | 9.0 (6.6, 11.3) | 0.68 |
| Admission category, n (%) | |||
| Medical | 10 (40.0) | 9 (36.0) | 0.88 |
| Surgical | 2 (8.0) | 3 (12.0) | |
| Post-operative trauma | 13 (52.0) | 13 (52.0) | |
| APACHE II, median (Q1, Q3) | 20.0 (14.0, 21.5) | 16 (13, 26) | 0.76 |
| Mechanical ventilation, n (%) | 25 (100) | 25 (100) | 1.00 |
| Sepsis on admission, n (%) | 3 (12.0) | 2 (8.0) | 0.64 |
| Vasopressor, n (%) | 18 (72.0) | 15 (60.0) | 0.37 |
| Hemoglobin (g/L), median (Q1, Q3) | 110 (97, 124) | 111 (97, 128) | 0.44 |
| INR, median (Q1, Q3) | 1.2 (1.0, 1.3) | 1.1 (1.0, 1.3) | 0.78 |
| SOFA Score Day 1, median (Q1, Q3) | 10.0 (8.5, 11.5) | 11 (10, 12) | 0.10 |
| PaO2: FiO2 ratio, median (Q1, Q3) | 211 (110, 286) | 115 (88, 200) | 0.11 |
| Platelets (×109/L), median (Q1, Q3) | 172 (153, 264) | 193 (176, 217) | 0.53 |
| Bilirubin, (μmol/L), median (Q1, Q3) | 11.8 (8.7, 27.7) | 19.0 (10.0, 29.1) | 0.44 |
| GCS, median (Q1, Q3) | 3 (3, 4) | 3 (3, 5) | 0.61 |
| Creatinine, (µmol/L), median (Q1, Q3) | 77 (74, 114) | 79 (69, 114) | 0.76 |
| C-reactive protein (mg/liter), median (Q1, Q3) | 156.5 (111.5, 199.0) | 132.0 (83.9, 187.0) | 0.54 |
| Serum lipid profile (mmol/liter), median (Q1, Q3) | |||
| Cholesterol | 2.5 (1.8, 2.9) | 2.6 (2.0, 3.1) | 0.50 |
| Triglycerides | 1.3 (1.0, 1.7) | 1.4 (0.9, 2.0) | 0.70 |
| HDL | 0.5 (0.4, 0.6) | 0.5 (0.3, 0.6) | 0.43 |
| LDL | 0.9 (0.7, 1.4) | 1.1 (0.8, 1.5) | 0.55 |
| Albumin (g/L), median (Q1, Q3) | 28.0 (24.5, 34.5) | 28 (25, 33) | 0.64 |
| Pre-albumin (g/L), median (Q1, Q3) | 0.12 (0.09, 0.13) | 0.11 (0.08, 0.15) | 0.88 |
| Hemoglobin A1c, median (Q1, Q3) | 0.06 (0.05, 0.06) | 0.06 (0.06, 0.07) | 0.33 |
| 24 hours urinary nitrogen excretion (mmol/L), median (Q1, Q3) | 234 (74, 321) | 274 (158, 381) | 0.23 |
| Transferrin (g/L), median (Q1, Q3) | 1.2 (1.0, 1.5) | 1.4 (1.2, 1.7) | 0.03 |
| Minute ventilation (L), median (Q1, Q3) | 9.9 (8.4, 10.8) | 10.2 (8.2, 11.3) | 0.93 |
| Maximum temperature (0C), median (Q1, Q3) | 37.1 (36.7, 37.6) | 37.3 (36.8, 37.9) | 0.48 |
BMI: body mass index; APACHE II: Acute Physiology and Chronic Health Evaluation II; INR: international normalized ratio; SOFA: Sequential Organ Failure Assessment; GCS: Glasgow coma scale PaO2:FiO2 ratio: the ratio of partial pressure of oxygen to the fraction of inspired oxygen; HDL: High density lipoproteins; LDL: Low density lipoproteins.
The denominators for all percentages is the N for each column. Continuous variables are represented as median (quartile 1 and quartile 3).
Daily caloric intake, protein intake, insulin, and glucose data in two groups.
| Variable | Permissive underfeeding n = 25 | Standard feeding n = 25 | P-value |
|---|---|---|---|
| Calculated caloric requirement (kcal/day), median (Q1, Q3) | 1746 (1585, 2075) | 1909 (1770, 2162) | 0.25 |
| Study caloric target (kcal/day) median (Q1, Q3) | 1071 (960, 1264) | 1909 (1770, 2162) | <0.0001 |
| Daily caloric intake | |||
| No. of kilocalories, median (Q1, Q3) | 990 (810.0, 1149.1) | 1339.1 (1136.1, 1695.1) | 0.004 |
| Percent of requirement, median (Q1, Q3) | 56.5 (51.1, 58.5) | 67.6 (55.7, 89.6) | 0.006 |
| Caloric source (kcal/day) median (Q1, Q3) | |||
| Enteral | 936.9 (7.9.3, 1018.4) | 1239.6 (1101.6, 1518.0) | 0.01 |
| Propofol | 85.4 (11.0, 141.8) | 78.6 (38.5, 232.7) | 0.45 |
| Intravenous dextrose | 0.0 (0.0, 17.9) | 0.0 (0.0, 29.10 | 0.51 |
| Total parenteral nutrition | 0 (0, 0) | 0 (0, 0) | 1.0 |
| Calculated protein requirement (g/day) median (Q1, Q3) | 84 (70, 95) | 88 (82, 97) | 0.16 |
| Daily total protein intake | |||
| No. of grams | 66.9 (47.0, 74.5) | 61.1 (48.5, 75.1) | 0.37 |
| Percent of requirement | 82.1 (69.0, 88.8) | 66.3 (50.3, 83.6) | 0.07 |
| Protein source (g/day), median (Q1, Q3) | |||
| Main enteral formula | 30.4 (25.0, 38.1) | 51.8 (32.5, 64.5) | 0.0007 |
| Supplemental enteral protein | 30.7 (22.3, 39.8) | 0.0 (0.0, 6.1) | <0.0001 |
| Parenteral protein | 0 (0, 0) | 0 (0, 0) | 0.34 |
| Duration of intervention (days) median (Q1, Q3) | 13 (7, 14) | 14 (8, 14) | 0.33 |
| Co-interventions | |||
| Insulin | |||
| Use, no. (%) | 10 (40.0) | 12 (48.0) | 0.68 |
| Dose (units/day), median (Q1, Q3) | 0.0 (0.0, 23.4) | 0.0 (0.0, 20.6) | 0.47 |
| Blood glucose (mmol/liter), median (Q1, Q3) | 7.7 (6.6, 11.8) | 8.4 (7.0, 11.0) | 0.85 |
| Enteral formulae on day 1†, n. (%) | |||
| Disease-non-specific | 15 (60.0) | 13 (52.0) | 0.59 |
| Disease-specific | 10 (40.0) | 12 (48.0) | |
| Medications given during the ICU stay – n. (%) | |||
| Beta blockers | 10 (40.0) | 11 (44.0) | 0.77 |
| Aspirin | 4 (16.0) | 5 (20.0) | 0.82 |
| Angiotensin-converting enzyme inhibitors | 1 (4.0) | 2 (8.0) | 0.55 |
| Angiotensin II receptor blockers | 0 (0.0) | 0 (0.0) | |
| Statins | 5 (20.0) | 4 (16.0) | 0.71 |
†Disease-nonspecific formula: Osmolite, Jevity, Promote, Ensure plus, Resource, Ensure, Resource plus, Jevity (1.2).
†Disease-specific formula: Glucerna, Nutric hepatic, Nepro, Pulmocare, Novasource Renal, Peptamen (1.0), Peptamen (1.2), Suplena, Oxepa.
Genes that were significantly upregulated or downregulated between study day 1 and 14 (global p value for the pathway ≤ 0.05).
| Pathway | Global p-value | Number of up- or downregulated genes | Total number of genes in the pathway |
|---|---|---|---|
| Cancer pathways | 0.00002 | 23 | 327 |
| Glycolysis/Gluconeogenesis | 0.00031 | 8 | 66 |
| Phospholipase | 0.00227 | 5 | 38 |
| Salvage pathways of pyrimidine deoxyribonucleotides | 0.00641 | 2 | 5 |
| Dolichyl-diphosphooligosaccharide biosynthesis | 0.01704 | 2 | 8 |
| Uracil degradation II (reductive) | 0.01704 | 2 | 8 |
| Thymine degradation | 0.01704 | 2 | 8 |
| Methylthiopropionate biosynthesis | 0.02600 | 1 | 1 |
| Pentose phosphate pathway | 0.02647 | 2 | 10 |
| MAPK signaling pathway | 0.03237 | 12 | 257 |
| N-Glycan biosynthesis | 0.03827 | 4 | 49 |
| NAD salvage pathway II | 0.04358 | 2 | 13 |
Figure 1Gene expression in the permissive underfeeding and standard feeding groups. Blue-to-red colors indicates gene expression signal intensity from downregulated to upregulated based on p-value generated by built-in pathway module in GeneSpring software using the hypergeometric method. The differential expression (Diff. Expr.) is calculated as the difference in gene expression signal intensity in the permissive underfeeding group and the standard feeding group from day 1 to 14 [(mean gene expression signal intensity in the permissive underfeeding group on day 14-day 1) − (mean gene expression signal intensity in the standard feeding on day 14- day 1)]. Genes are sorted according to the ascending differential expression.
Comparison of changes in gene expression signal intensity from day 1 to 14 in the permissive underfeeding and standard feeding groups.
| Gene Name | Change in gene expression (Day 14-Day 1) | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
| Permissive feeding | Standard feeding | β -coefficient | 95% CI | P value | β -coefficient | 95% CI | P value | |
|
| ||||||||
| Membrane-associated phospholipase A2 | −0.086 ± 0.192 | 0.102 ± 0.206 | −0.188 | −0.303, −0.074 | 0.002 | −0.194 | −0.319, −0.069 | 0.003 |
| Growth arrest and DNA damage inducible beta (GADD45B) | −0.098 ± 0.186 | 0.066 ± 0.287 | −0.163 | −0.303, −0.023 | 0.023 | −0.156 | −0.303, −0.009 | 0.038 |
| Pyruvate kinase, muscle (PKM) | −0.087 ± 0.151 | 0.007 ± 0.164 | −0.094 | −0.185, −0.003 | 0.043 | −0.085 | −0.184, 0.014 | 0.091 |
| Group IIE secretory phospholipase A2 (sPLA2-IIE) | −0.090 ± 0.218 | 0.033 ± 0.411 | −0.124 | −0.314, 0.067 | 0.198 | −0.139 | −0.347, 0.070 | 0.186 |
| 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase | −0.106 ± 0.141 | −0.008 ± 0.192 | −0.097 | −0.194, −0.0004 | 0.049 | −0.115 | −0.221, −0.010 | 0.033 |
| Phosphatase and tensin homolog (PTEN) | 0.042 ± 0.279 | 0.135 ± 0.271 | −0.093 | −0.251, 0.065 | 0.243 | −0.111 | −0.280, 0.057 | 0.190 |
| Transforming growth factor-β3 (TGF-β3) | −0.052 ± 0.126 | 0.004 ± 0.110 | −0.056 | −0.124, 0.011 | 0.102 | −0.057 | −0.131, 0.016 | 0.120 |
| Neuronal RAP1A (Member of RAS Oncogene family, RAP1A) | −0.063 ± 0.266 | −0.006 ± 0.169 | −0.057 | −0.185, 0.070 | 0.372 | −0.031 | −0.166, 0.103 | 0.641 |
| BRAF Proto-oncogene, Serine/threonine kinase (BRAF) | −0.083 ± 0.146 | −0.028 ± 0.146 | −0.055 | −0.139, 0.029 | 0.194 | −0.068 | −0.160, 0.024 | 0.144 |
| Calcium voltage-gated channel auxillary subunit (CACNB2) | −0.008 ± 0.131 | 0.031 ± 0.151 | −0.038 | −0.120, 0.043 | 0.348 | −0.061 | −0.147, 0.025 | 0.160 |
|
| ||||||||
| Aldehyde dehydrogenase 1 family member (ALDH1A3) | 0.012 ± 0.135 | −0.062 ± 0.139 | 0.074 | −0.004, 0.153 | 0.064 | 0.080 | −0.008, 0.167 | 0.072 |
| Pyruvate dehydrogenase E1 Beta subunit (PDHB) | 0.064 ± 0.164 | 0.002 ± 0.173 | 0.063 | −0.034, 0.160 | 0.199 | 0.042 | −0.064, 0.147 | 0.431 |
| ADP dependent glucokinase (ADPGK) | 0.107 ± 0.164 | 0.011 ± 0.149 | 0.096 | 0.006, 0.186 | 0.037 | 0.105 | 0.007, 0.204 | 0.036 |
| WNT family member 1 (WNT1) | 0.111 ± 0.260 | −0.006 ± 0.227 | 0.117 | −0.023, 0.258 | 0.099 | 0.125 | −0.024, 0.273 | 0.098 |
| UDP-N-acetylglucosamine transferase subunit ALG13 homolog | 0.013 ± 0.166 | −0.068 ± 0.137 | 0.081 | −0.006, 0.169 | 0.067 | 0.100 | 0.008, 0.192 | 0.033 |
| Peroxisomal NADH pyrophosphatase NUDT12 | 0.007 ± 0.206 | −0.077 ± 0.212 | 0.084 | −0.036, 0.205 | 0.164 | 0.050 | −0.078, 0.178 | 0.433 |
| Sonic hedgehog (SHH) | 0.131 ± 0.244 | −0.007 ± 0.301 | 0.139 | −0.019, 0.297 | 0.084 | 0.167 | −0.006, 0.340 | 0.058 |
| Vascular endothelial growth factor C (VEGF-C) | 0.111 ± 0.228 | −0.052 ± 0.155 | 0.163 | 0.051, 0.274 | 0.005 | 0.162 | 0.044, 0.280 | 0.008 |
| Cytochrome C, somatic (CYCS) | 0.019 ± 0.304 | −0.152 ± 0.246 | 0.171 | 0.013, 0.330 | 0.035 | 0.176 | 0.003, 0.349 | 0.046 |
| Pan2 protein | 0.132 ± 0.433 | −0.118 ± 0.340 | 0.249 | 0.026, 0.472 | 0.029 | 0.182 | −0.041, 0.406 | 0.108 |
Univariate analysis and multivariate linear regression models were carried out to assess the gene expression signal intensity in permissive underfeeding compared to standard feeding. In the multivariate model, we adjusted for age, the ratio of partial pressure of oxygen to the fraction of inspired oxygen (PaO2/FiO2) ratio and Sequential Organ Failure Assessment (SOFA) scores.